Cite
Sustained impact of subcutaneous immunotherapy among patients with allergic rhinitis who experienced treatment delay due to the COVID‐19 pandemic: A multicenter, two‐arm, real‐world study.
MLA
Zhou, Suizi, et al. “Sustained Impact of Subcutaneous Immunotherapy among Patients with Allergic Rhinitis Who Experienced Treatment Delay Due to the COVID‐19 Pandemic: A Multicenter, Two‐arm, Real‐world Study.” Clinical & Translational Allergy, vol. 12, no. 3, Mar. 2022, pp. 1–3. EBSCOhost, https://doi.org/10.1002/clt2.12122.
APA
Zhou, S., Liu, Y., Xue, J., Tang, J., Yu, Q., Qu, S., Zhang, S., Mo, B., Li, J., Liu, Y., Yang, Y., Wang, D., & Qiu, Q. (2022). Sustained impact of subcutaneous immunotherapy among patients with allergic rhinitis who experienced treatment delay due to the COVID‐19 pandemic: A multicenter, two‐arm, real‐world study. Clinical & Translational Allergy, 12(3), 1–3. https://doi.org/10.1002/clt2.12122
Chicago
Zhou, Suizi, Yibin Liu, Jianrong Xue, Jun Tang, Qingqing Yu, Shenhong Qu, Shaojie Zhang, et al. 2022. “Sustained Impact of Subcutaneous Immunotherapy among Patients with Allergic Rhinitis Who Experienced Treatment Delay Due to the COVID‐19 Pandemic: A Multicenter, Two‐arm, Real‐world Study.” Clinical & Translational Allergy 12 (3): 1–3. doi:10.1002/clt2.12122.